The present meta-analysis with newest and largest quantity of relevant publications confirmed that KRAS mutation is significantly associated with worse OS (HR=1.56) and DFS (HR=1.57), and also with inferior ORR (RR=0.21 and 0.66 for TKI and chemotherapy respectively) and PFS (HR=1.46 and 1.30 respectively) of EGFR-TKIs treatment or chemotherapy, compared with KRAS wild-type NSCLC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.